Related Experiment Videos
Cytokines and tumor vaccination
1Department of Hematology and Oncology, Hannover Medical School, Germany.
Cancer Biotherapy & Radiopharmaceuticals
|October 1, 1996
Summary
This study explored autologous tumor cell vaccines combined with cytokines as adjuvant therapy for advanced renal cell carcinoma. The treatment showed potential to improve disease-free survival and reduce relapse rates in patients post-surgery.
Area of Science:
- Oncology
- Immunotherapy
- Surgical Oncology
Background:
- Locally advanced renal cell carcinoma (RCC) carries a high risk of post-surgical relapse.
- Existing immunotherapeutic approaches for metastatic RCC suggest potential for adjuvant treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of autologous tumor cell vaccines combined with low-dose cytokines as a surgical adjuvant therapy for locally advanced RCC.
Main Methods:
- A phase II trial involved 208 patients with locally advanced RCC receiving autologous, Newcastle disease virus-modified, irradiated tumor cell vaccines.
- Vaccinations were administered subcutaneously weekly for 8-10 weeks, starting 4-10 weeks post-surgery.
- Treatment included low-dose recombinant interleukin-2 and recombinant interferon-alpha 2a.
Main Results:
- Follow-up of 203 patients showed a median disease-free survival of 21 months.
- Relapse occurred in 8.9% of patients (3% local, 5% lymph node, 4.5% distant metastases).
- Treatment was generally well-tolerated with mild, flu-like toxicity.
Conclusions:
- Adjuvant treatment with autologous tumor vaccines and cytokines demonstrated a potential improvement in disease-free survival for locally advanced RCC.
- The approach appears to be a safe and potentially effective strategy to reduce relapse after radical surgery.